Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073208 | 0.87 | MAPT (0.65) | MAPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL4907597 | 0.84 | LMNA (0.67) | MAPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL20241917 | 0.84 | KMT2A (0.51) | MAPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL15871928 | 0.82 | RAB9A (0.58) | MAPTKMT2AMEN1POLBLMNA | |
| SCHEMBL3374076 | 0.81 | MEN1 (0.57) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL20241695 | 0.81 | SHMT1 (0.62) | MAPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL20241864 | 0.81 | SHMT1 (0.64) | MAPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL31578670 | 0.80 | ALDH1A1 (0.60) | MAPTKMT2AMEN1LMNAGAA | |
| SCHEMBL11157975 | 0.79 | MEN1 (0.62) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL4905599 | 0.79 | PTPN11 (0.43) | MAPTSMN1; SMN2KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | MAPT 1858/4885SMN1; SMN2 3271/4885KMT2A 3602/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | MAPT 1786/4885SMN1; SMN2 3404/4885KMT2A 3530/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | MAPT 1786/4885SMN1; SMN2 3404/4885KMT2A 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.